Hsbc Holdings PLC Invests $228,000 in Twist Bioscience Corporation $TWST

Hsbc Holdings PLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,823 shares of the company’s stock, valued at approximately $228,000.

Several other institutional investors have also modified their holdings of TWST. ARK Investment Management LLC raised its position in Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock valued at $245,045,000 after purchasing an additional 645,730 shares during the last quarter. Vanguard Group Inc. raised its position in Twist Bioscience by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company’s stock valued at $230,356,000 after purchasing an additional 60,276 shares during the last quarter. Nuveen LLC purchased a new stake in Twist Bioscience in the 1st quarter valued at $31,960,000. American Century Companies Inc. raised its position in Twist Bioscience by 0.9% in the 1st quarter. American Century Companies Inc. now owns 763,406 shares of the company’s stock valued at $29,971,000 after purchasing an additional 7,054 shares during the last quarter. Finally, Northern Trust Corp raised its position in Twist Bioscience by 9.0% in the 4th quarter. Northern Trust Corp now owns 627,649 shares of the company’s stock valued at $29,167,000 after purchasing an additional 51,926 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TWST shares. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a research report on Monday, August 4th. Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average price target of $49.40.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $25.76 on Friday. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a fifty-two week low of $24.28 and a fifty-two week high of $55.33. The stock has a market cap of $1.55 billion, a PE ratio of -17.77 and a beta of 2.31. The firm’s fifty day simple moving average is $31.74 and its 200-day simple moving average is $34.88.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the sale, the chief financial officer directly owned 103,569 shares of the company’s stock, valued at approximately $3,951,157.35. This represents a 2.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,678 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the sale, the chief executive officer directly owned 645,782 shares in the company, valued at approximately $23,093,164.32. The trade was a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,250 shares of company stock worth $193,852. 3.01% of the stock is owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.